November 18, 2026
Trends in Tech & Life Sciences PIPEs & RDOs
U.S.-based technology and life sciences companies – excluding SPACs – conducted a total of 103 private investments in public equity (PIPEs) and registered direct offerings (RDOs) between January 1 and June 30, 2026, according to this mid-year report from Wilson Sonsini. Here are some notable trends:
• Rebound in life sciences transactions. The life sciences industry experienced a significant rebound from low transaction volumes seen in 2025. A total of 72 life sciences transactions in the first half of 2026 raised an aggregate of $4.5 billion, representing a 75.6% increase in number of transactions and a more than 100% increase in amounts raised.
• Transformative deals commanded premium pricing. Twelve life sciences transactions in 2026 were accompanied by transformative events, including strategic collaborations, pivots in corporate strategy, mergers or reverse mergers, in-licensing, and divestitures. These transactions tended to have more favorable terms. For example, nine such transactions involving the issuance of common stock or prepaid warrants priced at an average of a 12.3% premium to the pre-announcement stock price, compared to an average discount of 1.2% for common stock or prepaid warrant issuances by remaining life sciences companies.
• Large transactions to support AI investment. The top seven technology transactions raised approximately $1 billion or more, for an aggregate of approximately $11.6 billion, or 87.6% of the total proceeds in the technology industry. Six of the transactions included companies involved in the buildout of artificial intelligence services or infrastructure.
• Proposed regulatory changes may increase access to capital. In May 2026, the U.S. Securities and Exchange Commission (SEC) proposed a substantial revision of the framework for public offerings with the goal of facilitating capital formation in the public securities markets. The proposal could significantly expand access to registered offerings on Form S-3, including by removing limitations on transactions with smaller market capitalization, making the form available to issuers immediately after going public, and revising certain “timely filing” requirements. If adopted substantially as proposed, the SEC’s revisions would expand access to Form S-3, reduce execution friction in registered offerings, and extend capital markets flexibility to a broader range of reporting companies.
The report is limited to transactions in which the company raised at least $10 million and had at least one closing in the first half of 2026. In addition to discussing trends, the 44-page report also provides a primer on PIPEs and RDOs, along with pros & cons of each and other special considerations. New this year, it also examines 10 warrant inducement transactions by technology or life sciences companies. Here are some key findings on that topic:
In the 10 warrant inducement transactions reviewed, inducements included the following incentives:
• seven transactions (70%) included the issuance of new warrants and a temporary reduction of the existing warrants’ exercise price;
• two transactions (20%) provided only for the issuance of new warrants; and
• one transaction (10%) provided only for amendments to the existing warrant terms, consisting of a reduction in exercise price and extension of maturity.
In the nine transactions that included the issuance of new warrants, warrant coverage ranged from 100% to 300%, with an average of 175% and a median of 200%. Warrants carried a five-year term, in two instances supplemented by a shorter-term second tranche. In seven transactions, the company committed to seek stockholder approval for issuance of shares underlying the warrants. In all nine transactions with new warrants, the company agreed to file a resale registration statement with respect to the issuance of shares underlying the warrants.
– Liz Dunshee
Blog Preferences: Subscribe, unsubscribe, or change the frequency of email notifications for this blog.
UPDATE EMAIL PREFERENCESTry Out The Full Member Experience: Not a member of TheCorporateCounsel.net? Start a free trial to explore the benefits of membership.
START MY FREE TRIAL